Clinical characteristics
| Characteristic . | Overall . | MSKCC . | Duke . |
|---|---|---|---|
| Institution | 534 (100) | 409 | 125 |
| MSKCC | 409 (76.6) | ||
| Duke | 125 (23.4) | ||
| Mean age at auto-HCT, y (SD) | 58.4 (11.5) | 58.0 (11.7) | 59.9 (10.7) |
| Sex | |||
| Male | 329 (61.6) | 252 (61.6) | 77 (61.6) |
| Female | 205 (38.4) | 157 (38.4) | 48 (38.4) |
| Disease | |||
| Multiple myeloma | 272 (50.9) | 189 (46.2) | 83 (66.4) |
| Lymphoma | 227 (42.5) | 186 (45.5) | 41 (32.8) |
| Non-Hodgkin lymphoma | 200 (37.5) | 164 (40.1) | 36 (28.8) |
| Hodgkin lymphoma | 27 (5.0) | 22 (5.4) | 5 (4.0) |
| Amyloidosis | 35 (6.5) | 34 (8.3) | 1 (0.8) |
| Conditioning regimen | |||
| Melphalan | 305 (57.1) | 223 (54.5) | 82 (65.6) |
| Other melphalan-based regimen | 8 (1.5) | 5 (1.2) | 3 (2.4) |
| BEAM | 109 (20.4) | 82 (20.0) | 27 (21.6) |
| Other BEAM-based regimen | 46 (8.6) | 42 (10.2) | 4 (3.2) |
| Thiotepa-busulfan-cyclophosphamide | 47 (8.8) | 45 (11.0) | 2 (1.6) |
| TBI-based regimen | 3 (0.6) | 2 (0.5) | 1 (0.8) |
| Other* | 16 (3.0) | 10 (2.4) | 6 (4.8) |
| Disease status at transplant | |||
| Complete response/near complete response† | 171 (32.0) | 125 (30.6) | 46 (36.8) |
| Partial response | 183 (34.3) | 165 (40.3) | 18 (14.4) |
| Very good partial response‡ | 137 (25.7) | 85 (20.8) | 52 (41.6) |
| Relapse/refractory | 6 (1.1) | 2 (0.5) | 4 (3.2) |
| Progressive/stable disease | 27 (5.0) | 26 (6.4) | 1 (0.8) |
| Other | 10 (1.9) | 6 (1.5) | 4 (3.2) |
| Median follow-up of survivors, mo (IQR) | 26.6 (17.3-36.6) | 30.6 (19.7-39.4) | 19.1 (12.9-25.9) |
| Characteristic . | Overall . | MSKCC . | Duke . |
|---|---|---|---|
| Institution | 534 (100) | 409 | 125 |
| MSKCC | 409 (76.6) | ||
| Duke | 125 (23.4) | ||
| Mean age at auto-HCT, y (SD) | 58.4 (11.5) | 58.0 (11.7) | 59.9 (10.7) |
| Sex | |||
| Male | 329 (61.6) | 252 (61.6) | 77 (61.6) |
| Female | 205 (38.4) | 157 (38.4) | 48 (38.4) |
| Disease | |||
| Multiple myeloma | 272 (50.9) | 189 (46.2) | 83 (66.4) |
| Lymphoma | 227 (42.5) | 186 (45.5) | 41 (32.8) |
| Non-Hodgkin lymphoma | 200 (37.5) | 164 (40.1) | 36 (28.8) |
| Hodgkin lymphoma | 27 (5.0) | 22 (5.4) | 5 (4.0) |
| Amyloidosis | 35 (6.5) | 34 (8.3) | 1 (0.8) |
| Conditioning regimen | |||
| Melphalan | 305 (57.1) | 223 (54.5) | 82 (65.6) |
| Other melphalan-based regimen | 8 (1.5) | 5 (1.2) | 3 (2.4) |
| BEAM | 109 (20.4) | 82 (20.0) | 27 (21.6) |
| Other BEAM-based regimen | 46 (8.6) | 42 (10.2) | 4 (3.2) |
| Thiotepa-busulfan-cyclophosphamide | 47 (8.8) | 45 (11.0) | 2 (1.6) |
| TBI-based regimen | 3 (0.6) | 2 (0.5) | 1 (0.8) |
| Other* | 16 (3.0) | 10 (2.4) | 6 (4.8) |
| Disease status at transplant | |||
| Complete response/near complete response† | 171 (32.0) | 125 (30.6) | 46 (36.8) |
| Partial response | 183 (34.3) | 165 (40.3) | 18 (14.4) |
| Very good partial response‡ | 137 (25.7) | 85 (20.8) | 52 (41.6) |
| Relapse/refractory | 6 (1.1) | 2 (0.5) | 4 (3.2) |
| Progressive/stable disease | 27 (5.0) | 26 (6.4) | 1 (0.8) |
| Other | 10 (1.9) | 6 (1.5) | 4 (3.2) |
| Median follow-up of survivors, mo (IQR) | 26.6 (17.3-36.6) | 30.6 (19.7-39.4) | 19.1 (12.9-25.9) |
All data are presented as no. (%), unless otherwise indicated. For the categories listed herein, there were no missing values. Percentages may not total 100 due to rounding.
BEAM, carmustine, etoposide, cytarabine, and melphalan; IQR, interquartile range; SD, standard deviation; TBI, total body irradiation.
Other conditioning regimens (with numbers of patients treated in parentheses) included carmustine-thiotepa (1), bendamustine-cytarabine-etoposide-melphalan (1), carmustine-etoposide-cyclophosphamide (7), cyclophosphamide-carmustine-etoposide (1), gemcitabine-busulfan-melphalan (1), mitoxantrone-cyclophosphamide-carmustine (1), rituximab-ibritumomab-carmustine-etoposide-cytarabine-melphalan (1), rituximab-bendamustine-melphalan (2), and thiotepa-carmustine (1).
Near complete response for myeloma was defined as serum and urine M-protein detectable by immunoelectrophoresis, but not by electrophoresis and <5% plasma cells in bone marrow.
Very good partial response does not include lymphoma patients.